Design Therapeutics, Inc. Common Stock (DSGN) Stock Price

DSGNStock

$15.11+167.91%52W

Market Cap$945.61M

P/E—

PEG Ratio—

Div yield—

Beta1.66

DSGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)30.62%

Price vs S&P 500 (4W)16.88%

VGM Score81.37

DSGN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	-$0.34	-$0.32	+7.06%(+$0.02)
Q1 2026	Apr 28, 2026	-$0.33	-$0.29	+13.17%(+$0.04)
Q4 2025	Mar 9, 2026	-$0.35	-$0.27	+23.73%(+$0.08)
Q3 2025	Nov 5, 2025	-$0.34	-$0.30	+12.62%(+$0.04)
Q2 2025	Aug 7, 2025	-$0.33	-$0.34	-3.03%(-$0.01)

DSGN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

4.31

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
DSGNDesign Therapeutics, Inc. Common Stock	—	—	A	$15.11
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Design Therapeutics, Inc. Common Stock

Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC molecules, a proprietary platform of small-molecule therapeutics designed to treat inherited diseases caused by nucleotide repeat expansions such as Friedreich Ataxia, Myotonic Dystrophy, Huntington's Disease, and Fuchs Endothelial Corneal Dystrophy. The company's GeneTAC candidates are designed to address the underlying genetic causes of these conditions, offering potential disease-modifying treatments for currently incurable genetic disorders.